Recent News
New Haven, CT, October 29, 2020 – Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Our Sciences
News
NEW HAVEN, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific […] Read More
CD38-Targeting Molecule To be Evaluated in Multiple Patient Populations NEW HAVEN, Conn., Sept. 08, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals, […] Read More
A Novel First in Class ex vivo Combination Between NK cells & a CD38 Targeting Antibody Recruiting Molecule as a […] Read More
By Jessica Cohen For the Gazette MILFORD, Pa. – Infectious disease specialist Doug Manion came to Milford, Pa, and COVID-19 […] Read More
Events
